Sanyou Bio and FatiAbGen Forge AI-STAL Alliance for Korea and Global Markets
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and South Korea’s FatiAbGen Co., Ltd. announced a comprehensive strategic...
December 2025
Mabwell’s 9MW1911 Cuts COPD Exacerbations by 30% in Phase 2a, FDA Accepts US Trial Application
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its ST2‑blocking monoclonal antibody 9MW1911 has...
Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR‑T Combination for Advanced Solid Tumors
Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co‑development...
Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech
Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New...
iRegene’s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy
iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving...
Proviva’s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost
Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD 30 million led...